Literature DB >> 12107114

Complicated mechanisms of class II transactivator transcription deficiency in small cell lung cancer and neuroblastoma.

Takuya Yazawa1, Takaaki Ito, Hiroshi Kamma, Takehisa Suzuki, Koji Okudela, Hiroyuki Hayashi, Hisashi Horiguchi, Takesaburo Ogata, Hideaki Mitsui, Masaichi Ikeda, Hitoshi Kitamura.   

Abstract

Small cell lung cancer (SCLC) and neuroblastoma (NB), the most aggressive adult and infant neuroendocrine cancers, respectively, are immunologically characterized by a severe reduction in major histocompatibility complex (MHC) that is indispensable for anti-tumor immunity. We had reported that the severe reduction of MHC in SCLC was caused by a deficient interferon (IFN)-gamma-inducible expression of class II transactivator (CIITA) that is known as a very important transcription factor for IFN-gamma-inducible class II and class I MHC expression (Yazawa T, Kamma H, Fujiwara M, Matsui M, Horiguchi H, Satoh H, Fujimoto M, Yokohama K, Ogata T: Lack of class II transactivator causes severe deficiency of HLA-DR expression in small cell lung cancer. J Pathol 1999, 187:191-199). Here, we demonstrate that the reduction of MHC in NB was also caused by a deficient IFN-gamma-inducible expression of CIITA and that the deficiency in SCLC and NB was caused by similar mechanisms. Human achaete-scute complex homologue (HASH)-1, L-myc, and N-myc, which are specifically overexpressed in SCLC and NB, bound to the E-box in CIITA promoter IV and reduced the transcriptional activity. Anti-sense oligonucleotide experiments revealed that overexpressed L-myc and N-myc lie upstream in the regulatory pathway of HASH-1 expression. The expression of HASH-1 was also up-regulated by IFN-gamma. Our results suggest that SCLC and NB have complicated mechanisms of IFN-gamma-inducible CIITA transcription deficiency through the overexpressed HASH-1, L-myc, and N-myc. These complicated mechanisms may play an important role in the escape from anti-tumor immunity.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107114      PMCID: PMC1850684          DOI: 10.1016/S0002-9440(10)64181-8

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  34 in total

1.  The induction of major histocompatibility complex class II expression is sufficient for the direct activation of human CD4+ T cells by porcine vascular endothelial cells.

Authors:  S Yun; M L Rose; J W Fabre
Journal:  Transplantation       Date:  2000-03-15       Impact factor: 4.939

2.  Induction of melanoma-associated antigen systemic immunity upon intratumoral delivery of interferon-gamma retroviral vector in melanoma patients.

Authors:  S Fujii; S Huang; T C Fong; D Ando; F Burrows; D J Jolly; J Nemunaitis; D S Hoon
Journal:  Cancer Gene Ther       Date:  2000-09       Impact factor: 5.987

3.  Loss of N-myc function results in embryonic lethality and failure of the epithelial component of the embryo to develop.

Authors:  B R Stanton; A S Perkins; L Tessarollo; D A Sassoon; L F Parada
Journal:  Genes Dev       Date:  1992-12       Impact factor: 11.361

4.  Expression of MHC class II antigens in human lung cancer cells.

Authors:  H Kamma; T Yazawa; T Ogata; H Horiguchi; T Iijima
Journal:  Virchows Arch B Cell Pathol Incl Mol Pathol       Date:  1991

5.  Small cell lung carcinomas express shared and private tumor antigens presented by HLA-A1 or HLA-A2.

Authors:  K Yamazaki; G Spruill; J Rhoderick; J Spielman; N Savaraj; E R Podack
Journal:  Cancer Res       Date:  1999-09-15       Impact factor: 12.701

6.  Differential expression of myc family genes during murine development.

Authors:  K A Zimmerman; G D Yancopoulos; R G Collum; R K Smith; N E Kohl; K A Denis; M M Nau; O N Witte; D Toran-Allerand; C E Gee
Journal:  Nature       Date:  1986 Feb 27-Mar 5       Impact factor: 49.962

7.  Suppression of MHC class I gene expression by N-myc through enhancer inactivation.

Authors:  M Lenardo; A K Rustgi; A R Schievella; R Bernards
Journal:  EMBO J       Date:  1989-11       Impact factor: 11.598

8.  Markedly decreased expression of class I histocompatibility antigens, protein, and mRNA in human small-cell lung cancer.

Authors:  A Doyle; W J Martin; K Funa; A Gazdar; D Carney; S E Martin; I Linnoila; F Cuttitta; J Mulshine; P Bunn
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

9.  Basic helix-loop-helix transcription factors regulate the neuroendocrine differentiation of fetal mouse pulmonary epithelium.

Authors:  T Ito; N Udaka; T Yazawa; K Okudela; H Hayashi; T Sudo; F Guillemot; R Kageyama; H Kitamura
Journal:  Development       Date:  2000-09       Impact factor: 6.868

10.  Characterization of antigen-presenting properties of tumour cells using virus-specific cytotoxic T lymphocytes.

Authors:  D C Spierings; E Agsteribbe; J Wilschut; A Huckriede
Journal:  Br J Cancer       Date:  2000-04       Impact factor: 7.640

View more
  17 in total

1.  Antitumor activity of CD56-chimeric antigen receptor T cells in neuroblastoma and SCLC models.

Authors:  Denise L Crossland; Warren L Denning; Sonny Ang; Simon Olivares; Tiejuan Mi; Kirsten Switzer; Harjeet Singh; Helen Huls; Kate S Gold; Bonnie S Glisson; Laurence J Cooper; John V Heymach
Journal:  Oncogene       Date:  2018-04-06       Impact factor: 9.867

Review 2.  Biological Consequences of MHC-II Expression by Tumor Cells in Cancer.

Authors:  Margaret L Axelrod; Rebecca S Cook; Douglas B Johnson; Justin M Balko
Journal:  Clin Cancer Res       Date:  2018-11-21       Impact factor: 12.531

Review 3.  HLA class II antigen-processing pathway in tumors: Molecular defects and clinical relevance.

Authors:  Barbara Seliger; Matthias Kloor; Soldano Ferrone
Journal:  Oncoimmunology       Date:  2017-02-06       Impact factor: 8.110

4.  Relationship between polymorphism of class II transactivator gene promoters and chronic hepatitis B.

Authors:  Ying-Ren Zhao; Ling Gong; Ying-Li He; Fang Liu; Chang Lu
Journal:  World J Gastroenterol       Date:  2005-02-14       Impact factor: 5.742

Review 5.  Infiltrating T lymphocytes in the tumor microenvironment of small cell lung cancer: a state of knowledge review.

Authors:  Yamei Chen; Ying Jin; Xiao Hu; Ming Chen
Journal:  J Cancer Res Clin Oncol       Date:  2022-01-08       Impact factor: 4.553

6.  Growth regulation via insulin-like growth factor binding protein-4 and -2 in association with mutant K-ras in lung epithelia.

Authors:  Hanako Sato; Takuya Yazawa; Takehisa Suzuki; Hiroaki Shimoyamada; Koji Okudela; Masaichi Ikeda; Kenji Hamada; Hisafumi Yamada-Okabe; Masayuki Yao; Yoshinobu Kubota; Takashi Takahashi; Hiroshi Kamma; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2006-11       Impact factor: 4.307

Review 7.  Mechanisms of neuroendocrine differentiation in pulmonary neuroendocrine cells and small cell carcinoma.

Authors:  Takaaki Ito; Naoko Udaka; Kohji Okudela; Takuya Yazawa; Hitoshi Kitamura
Journal:  Endocr Pathol       Date:  2003       Impact factor: 3.943

Review 8.  Small cell lung cancer: significance of RB alterations and TTF-1 expression in its carcinogenesis, phenotype, and biology.

Authors:  Hitoshi Kitamura; Takuya Yazawa; Hanako Sato; Koji Okudela; Hiroaki Shimoyamada
Journal:  Endocr Pathol       Date:  2009       Impact factor: 3.943

9.  Class II transactivator (CIITA) deficiency in tumor cells: complicated mechanisms or not?

Authors:  Peter J van den Elsen; Nienke van der Stoep
Journal:  Am J Pathol       Date:  2003-07       Impact factor: 4.307

10.  Neuroendocrine cancer-specific up-regulating mechanism of insulin-like growth factor binding protein-2 in small cell lung cancer.

Authors:  Takuya Yazawa; Hanako Sato; Hiroaki Shimoyamada; Koji Okudela; Tetsukan Woo; Michihiko Tajiri; Takashi Ogura; Nobuo Ogawa; Takehisa Suzuki; Hideaki Mitsui; Jun Ishii; Chie Miyata; Masashi Sakaeda; Kazuya Goto; Korehito Kashiwagi; Munetaka Masuda; Takashi Takahashi; Hitoshi Kitamura
Journal:  Am J Pathol       Date:  2009-08-13       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.